Home / Stocks / Lupin Limited
LUPIN

Lupin Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,998.8

Change

+26.9 (1.36%)

Open

₹1,969.0

Prev. Close

₹1,971.9

Day High

₹1,998.9

Day Low

₹1,956.4

Volume Analysis

Traded

362,371

Delivered

213,968

Delivery %

59.05%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (28.7%)
  • •Strong operating margin (30.0%)

Weaknesses (0)

No signal for this stock

Opportunities (3)

  • •Strong 3-year EPS growth (131.1%)
  • •Strong 3-year revenue growth (18.9%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹2,055.5 ₹2,027.2 ₹2,013.0 ₹1,984.7 ₹1,970.5 ₹1,942.2 ₹1,928.0
Fibonacci ₹2,027.2 ₹2,010.97 ₹2,000.94 ₹1,984.7 ₹1,968.47 ₹1,958.44 ₹1,942.2
Camarilla ₹2,010.49 ₹2,006.59 ₹2,002.7 ₹1,984.7 ₹1,994.9 ₹1,991.01 ₹1,987.11

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-4.95%

1 Week

-0.8%

1 Month

+1.77%

3 Months

-9.22%

6 Months

-12.4%

1 Year

-1.58%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹1,174.97

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

19.73%

Net margin 16.98% × asset turnover 0.7x × equity multiplier 1.66x

Company Overview

Sector

Healthcare

Market Cap

₹89,994 Cr

P/E (TTM)

16.0

ROE

28.7%

Book Value

₹526.0

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 18 Nov 2026. Not investment advice.

TopFund Analysis

Lupin Limited holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 76/100. The strongest factor is Financial Strength (100/100), while Momentum (12/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (28.7%); strong operating margin (30.0%). Strong 3-year EPS growth (131.1%).

TopFund Score — Fundamentals Quality

76/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

89

Valuation

53

Cash Flow

75

Corporate Governance

81

Momentum

12

Institutional Ownership

66

Business Quality

97

Risk & Volatility

69

Liquidity

89

From Screener.in

  • +Company has delivered good profit growth of 37.0% CAGR over last 5 years
  • +Company has been maintaining a healthy dividend payout of 17.1%
  • +Company's working capital requirements have reduced from 46.4 days to 28.0 days

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Newspaper Publication regarding the Notice of Postal Ballot and Remote E-Voting.

Sandoz launched Lupin’s Ranluspec biosimilar ranibizumab across Europe, excluding Germany, after European Commission approval.

Transcript of Q2 FY2027 Earnings Conference Call.

Copy of Newspaper publication in respect of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 5,039 5,197 4,961 5,600 5,673 5,768 5,667 6,268 7,048 7,168 7,475 8,277 7,827
Expenses + 4,121 4,159 3,964 4,359 4,332 4,412 4,346 4,541 4,706 4,906 4,989 5,827 5,783
Operating Profit 918 1,038 997 1,241 1,340 1,356 1,321 1,727 2,341 2,262 2,486 2,450 2,044
OPM % 18.0% 20.0% 20.0% 22.0% 24.0% 24.0% 23.0% 28.0% 33.0% 32.0% 33.0% 30.0% 26.0%
Other Income + 40 29 29 68 42 54 57 79 90 -312 9 130 127
Interest 81 74 71 68 71 67 89 92 108 115 120 110 106
Depreciation 248 257 457 248 257 271 393 299 317 313 447 453 486
Profit before tax 630 736 498 993 1,055 1,071 896 1,416 2,007 1,522 1,928 2,017 1,580
Tax % 21.0% 16.0% 26.0% 19.0% 19.0% 20.0% 13.0% 14.0% 26.0% 22.0% 24.0% 30.0% 27.0%
Net Profit + 495 619 368 806 859 859 782 1,221 1,485 1,181 1,469 1,417 1,155
EPS in Rs 11 13 8 18 19 19 17 27 32 26 32 31 25
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 22 20 12 16 13 11 14 12 24 24 32 32 11

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 12,770 14,256 17,367 15,797 14,665 15,375 15,163 16,405 16,642 20,011 22,708 27,958 30,746
Expenses + 9,146 10,564 12,865 12,649 12,104 13,020 12,596 16,187 14,921 16,211 17,430 19,798 21,505
Operating Profit 3,624 3,691 4,502 3,148 2,561 2,355 2,567 219 1,721 3,800 5,278 8,160 9,241
OPM % 28.0% 26.0% 26.0% 20.0% 17.0% 15.0% 17.0% 1.3% 10.0% 19.0% 23.0% 29.0% 30.0%
Other Income + 235 184 106 -1,310 91 -134 138 210 151 131 202 523 -45
Interest 10 59 153 204 302 363 141 143 274 312 295 434 450
Depreciation 435 487 912 1,086 846 970 887 1,659 881 1,197 1,169 1,376 1,698
Profit before tax 3,415 3,329 3,543 547 1,503 887 1,676 -1,372 716 2,422 4,015 6,873 7,047
Tax % 28.0% 32.0% 28.0% 53.0% 59.0% 130.0% 27.0% 10.0% 38.0% 20.0% 18.0% 22.0% —
Net Profit + 2,444 2,270 2,565 258 615 -270 1,228 -1,528 448 1,936 3,306 5,355 5,221
EPS in Rs 53 50 57 6 13 -6 27 -34 9 42 72 117 114
Dividend Payout % 14.0% 15.0% 13.0% 90.0% 37.0% -101.0% 24.0% -12.0% 42.0% 19.0% 17.0% 15.0% —
Sales growth 13 12 22 -9 -7 5 -1 8 1 20 13 23 24

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 8,784 11,073 13,407 13,487 13,652 12,446 13,712 12,062 12,374 14,199 17,112 22,357 23,959
Borrowings + 537 7,178 7,966 7,143 8,496 6,305 4,783 4,158 4,542 2,922 5,448 6,616 6,180
Other Liabilities + 3,642 3,957 4,749 5,300 5,423 5,968 4,844 5,340 5,794 6,539 6,327 9,082 9,680
Total Liabilities 13,054 22,298 26,212 26,020 27,661 24,810 23,430 21,651 22,800 23,751 28,978 38,146 39,911
Fixed Assets + 4,368 8,717 11,033 10,362 11,087 7,938 7,881 7,382 8,355 8,878 9,719 10,994 13,332
CWIP 576 2,702 2,133 2,598 1,640 940 1,066 1,146 1,238 773 517 1,016 931
Investments 1,658 16 2,136 262 2,295 2,374 2,455 900 517 1,075 1,146 3,670 4,456
Other Assets + 6,451 10,862 10,910 12,798 12,639 13,557 12,028 12,224 12,690 13,026 17,596 22,466 21,191
Total Assets 13,054 22,298 26,212 26,020 27,661 24,810 23,430 21,651 22,800 23,751 28,978 38,146 39,911
Equity Capital 90 90 90 90 90 91 91 91 91 91 91 91 91

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 2,733 -382 4,114 1,751 1,666 1,469 1,822 367 1,897 3,648 3,000 7,334
Cash from Investing Activity + -1,034 -6,769 -2,527 470 -3,282 1,107 -1,240 1,292 -1,287 -1,712 -4,172 -3,865
Cash from Financing Activity + -197 5,836 433 -1,492 744 -891 -1,885 -1,572 -337 -2,184 1,732 -846
Net Cash Flow 1,502 -1,315 2,019 729 -872 1,685 -1,303 87 273 -248 560 2,624
Free Cash Flow 1,865 -6,164 1,513 261 706 798 1,150 -531 436 2,732 1,347 5,527
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 101 21 117 73 102 84 99 146 124 105 74 105

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 47.04% → 46.84%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 7.1% 6.93% 6.92% 6.44% 6.27% 6.21% 6.28% 6.06% 6.04% 6.13% 6.08% 6.08%
Promoters 47.04% 47.01% 46.99% 46.96% 46.94% 46.91% 46.9% 46.89% 46.89% 46.85% 46.85% 46.84%
Government 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
FII 16.11% 18.29% 19.32% 21.5% 22.04% 21.46% 21.25% 20.5% 21.5% 21.7% 22.42% 23.28%
DII 29.72% 27.76% 26.77% 25.1% 24.73% 25.41% 25.55% 26.56% 25.58% 25.32% 24.65% 23.78%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Lupin Limited (this stock) 89,994 16.0 3.75 28.7%
Manipal Health Enterpri L 89,630 95.6 5.36 12.7%
Max Healthcare Ins Ltd 99,557 70.1 8.82 14.7%
Aurobindo Pharma Ltd 104,215 25.7 2.64 10.1%
Glenmark Pharmaceuticals 73,937 36.5 6.59 23.6%
Mankind Pharma Limited 108,424 46.5 6.16 13.1%
Cipla Ltd 112,563 36.2 3.18 11.6%

Which Mutual Funds Hold Lupin Limited?

Frequently Asked Questions about Lupin Limited

Community Sentiment

What are other investors saying about Lupin Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.